|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00541801 |
|
Date of registration:
|
08/10/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography
|
|
Scientific title:
|
Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography in Patients With Cytostatic Therapies |
|
Date of first enrolment:
|
March 2007 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00541801 |
|
Study type:
|
Interventional |
|
Study design:
|
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
|
|
|
Countries of recruitment
|
|
Switzerland
| | | | | | | |
|
Contacts
|
|
Name:
|
Paul Erne, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Luzerner Kantonsspital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with malignant disease with scheduled anthracycline and trastuzumab therapy
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Antineoplastic Agents
|
|
Heart Failure, Congestive
|
|
Intervention(s)
|
|
Device: Doppler-echocardiography and acoustic cardiography
|
|
Primary Outcome(s)
|
|
Changes of echocardiographic parameters and changes of electromechanical activation time (EMAT)and development of third heart sound as indicators of congestive heart failure
[Time Frame: Repeated measurements over a year]
|
|
Secondary Outcome(s)
|
|
Development of clinically overt congestive heart failure
[Time Frame: One year]
|
|
Secondary ID(s)
|
|
Audicor-Oncology
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|